Industry

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 Results demonstrate the potential for Camzyos to be the first targeted pharmacological therapy for the treatment of oHCM in adolescents Safety profile of Camzyos in adolescents was similar to established profile in … [Read more…]

Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC

Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe hypertension SOUTH SAN FRANCISCO, Calif., & PRINCETON, N.J.–(BUSINESS WIRE)–#ACC26—Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root … [Read more…]

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with … [Read more…]

Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD) that detects early signs of PH, a serious and progressive condition affecting the lungs and right side of the heart. The algorithm, which previously received FDA Breakthrough … [Read more…]

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Cobenfy—Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when switching adult outpatients with schizophrenia from … [Read more…]

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna … [Read more…]

Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk

Arizona health plan continues its longstanding support of cardiovascular research and prevention at the Phoenix Heart Walk PHOENIX–(BUSINESS WIRE)–#Aetna—Banner|Aetna, an Arizona-based health plan offering integrated coverage and care through a partnership between Banner Health and Aetna, a CVS Health company, is participating in the 2026 Phoenix Heart Walk on March 28. Organized by the American … [Read more…]

“Cold-blooded decision on hospital funding,” says CUPE in response to Ford government’s 2026 budget

TORONTO–(BUSINESS WIRE)–The real dollar hospital funding cut announced in the 2026 provincial budget will intensify the crisis in Ontario’s hospitals, which are already funded at the lowest rate in the country, says the Canadian Union of Public Employees. “The government increased hospital funding by four per cent – a real cut of two per cent … [Read more…]

Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors

Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company’s Sustained Value Destruction, Lack of Permanent Leadership, and Board’s Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed NEW YORK–(BUSINESS WIRE)–Irenic … [Read more…]

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

2025 was a turning point with key regulatory milestones providing a solid foundation for 2026. Cash runway is projected to extend through December 2026. Preparation of the Phase III RECOVER study is ongoing, including financing related to the trial. Note: See paragraph on Estimated Full-Year 2025 Consolidated Financial Results at the end of this Press … [Read more…]